Search
Isopropamide
go.drugbank.com/drugs/DB01625ApprovedVet approvedWithdrawnIt is used in the treatment of peptic ulcer and other gastrointestinal disorders marked by hyperacidity and hypermotility.
DDP733
go.drugbank.com/drugs/DB05049InvestigationalSerotonin is a neurotransmitter that is known to be involved in the control of the gastrointestinal (GI) system. … DDP733 is an oral prokinetic drug which Dynogen is developing as a treatment for both Irritable Bowel Syndrome with constipation (IBS-c) and nocturnal gastroesophageal reflux disease (NGERD).
PSN9301
go.drugbank.com/drugs/DB05001ExperimentalPSN9301 is an oral small molecule inhibitor of Dipeptidyl Peptidase IV (DP-IV), being developed for the treatment of type 2 diabetes. … PSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical and clinical data indicate that it may be an ideal product candidate for meal-related dosing.
Trodusquemine
go.drugbank.com/drugs/DB06333InvestigationalIt has demonstrated the ability to stimulate regeneration of heart and multiple other tissues in animal models [A176600].
Dexpramipexole
go.drugbank.com/drugs/DB15130InvestigationalFrom the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)). … Dexpramipexole is under investigation in clinical trial NCT01511029 (Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured
Categories: Compounds used in a research, industrial, or household settingEthyl biscoumacetate
go.drugbank.com/drugs/DB08794ApprovedWithdrawnEthyl biscoumacetate is a courmarin that is used as an anticoagulant. It has actions similar to those of Warfarin. (From Martindale, The Extra Pharmacopoeia, 30th ed, p226)
Pomaglumetad methionil
go.drugbank.com/drugs/DB05096InvestigationalLY2140023 is an investigational drug from Lilly, which is being developed as a new treatment option for schizophrenia. … Further studies are planned or are ongoing to learn more about the safety and effectiveness, including determining an optimal therapeutic dose for LY2140023.
Albinterferon Alfa-2B
go.drugbank.com/drugs/DB05396InvestigationalIn response to an FDA ruling, Novartis and Human Genome Sciences announced on October 5, 2010 that they ceased development of the drug. … The drug was under investigation as an alternative to pegylated IFN-α-2a for the treatment of hepatitis C.
Aldoxorubicin
go.drugbank.com/drugs/DB06013InvestigationalAldoxorubicin, an antineoplastic agents, is an albumin-binding prodrug of doxorubicin.
Girentuximab
go.drugbank.com/drugs/DB05304InvestigationalGirentuximab is a monoclonal chimeric (mouse/human) antibody directed against carbonic anhydrase IX, an antigen expressed in 95% of clear cell renal cell carcinomas (RCC).